Nuvalent Insider Sold Shares Worth $442,980, According to a Recent SEC Filing

MT Newswires11/05 05:50

Reported Earlier: New Report Highlights Nuvectis Pharma's NXP900 Synergy In NSCLC And Anticipates Upcoming NXP800 Data; Positions Nuvectis Among Precision Oncology Leaders Like Nuvalent ($6.6B) And Summit Therapeutics ($15B)

Benzinga10/28 23:51

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Businesswire10/28 20:21

UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus

Seeking Alpha10/25 03:32

Nuvalent Initiated at Neutral by UBS

Dow Jones10/24 20:05

UBS Initiates Coverage On Nuvalent With Neutral Rating, Announces Price Target of $100

Benzinga10/24 19:55